"First of all, the Novartis trial is only for patients with PSMA-positive tumors, while the Exelixis study doesn’t have that restriction. But patients must have measurable disease to be eligible for CONTACT-02, while PSMAfore didn’t require that."...I foresee a cat fight!
Combination of Cabometyx and Tecentri... - Advanced Prostate...
Combination of Cabometyx and Tecentriq used in patients with mCRPC, could even be better than Pluvicto?
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Or a crossover arm for each.
Cabometyx and Tecentriq may prolong life or progression free survival, but they have a lot of severe TRAEs. IMHO these are very toxic drugs for the benefits they may offer.
Not what you're looking for?
You may also like...
Pluvicto+Xtandi Delays Progression Better than Xtandi-alone in mCRPC
Significant improvement in progression-free survival, PSA, and pain scores. Side effects were...
It now Seems indisputable that therapies in combination with ADT are better than ADT alone
have been shown to extend life when added early while still castrate sensitive.
Schwah
Oh guys, this one is good for mCRPC: Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with mCRPC
promise-for-patients-with-metastatic-prostate-cancer/
https://clinicaltrials.gov/study/NCT05544227...
VISION trial results of Lu-177-PSMA-617
esult-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer
Pluvicto #1 result-after six weeks
Pluvicto Supply easing?
Trials for alternatives to Pluvicto?
